Impaired Absorption of Insulin Aspart From Lipohypertrophic Injection Sites

• Published in: Diabetes care Vol. 28; no. 8; pp. 2025 - 2027
• Main Authors: Johansson, Unn-Britt, Amsberg, Susanne, Hannerz, Lena, Wredling, Regina, Adamson, Ulf, Arnqvist, Hans J, Lins, Per-Eric
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Diabetes Association 01-08-2005
• Subjects: Biological and medical sciences; Blood Glucose - metabolism; Body Mass Index; Caring sciences; Diabetes; Diabetes Mellitus, Type 1 - drug therapy; Diabetes Mellitus, Type 1 - metabolism; Diabetes. Impaired glucose tolerance; Dosage and administration; Drug dosages; Drug therapy; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Glycated Hemoglobin A - metabolism; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - pharmacokinetics; Injections, Subcutaneous - adverse effects; Insulin; Insulin - administration & dosage; Insulin - analogs & derivatives; Insulin - blood; Insulin - pharmacokinetics; Insulin Aspart; INTERDISCIPLINARY RESEARCH AREAS; Lipodystrophy - etiology; Male; Medical sciences; Medical treatment; MEDICIN; Medicin och hälsovetenskap; MEDICINE; Middle Aged; Nursing; Omvårdnad; Plasma; Plasma injection; Skin Absorption; TVÄRVETENSKAPLIGA FORSKNINGSOMRÅDEN; Type 1 diabetes; Vårdvetenskap; Insulin aspart; Injection site; Absorption
• ISSN: 0149-5992; 1935-5548; 1935-5548
• DOI: 10.2337/diacare.28.8.2025

Johansson et al investigate whether the absorption of a single subcutaneous dose of insulin aspart is impaired when administered to lipohypertrophic tissue in patients with type 1 diabetes. They found that the absorption of insulin aspart was impaired in lipohypertrophic tissue, yielding a 25% lower Cmax of plasma insulin. They believe that it is likely to be of clinical importance.